Barclays reiterates Overweight on Incyte (INCY) despite mixed Ph3 trial results
Tweet Send to a Friend
Barclays analyst Etzer Darout reiterated an Overweight rating and $117.00 price target on Incyte (NASDAQ: INCY)The analyst commented, "SVR35 endpoint ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


